TNF Inhibitors Market (Drug - Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab; Application - Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
- Rep Id : XPLREP2461
- Published On : August, 2018
- No. of Pages : 198
- Category : Healthcare
- Publisher : Transparency Market Research
Global TNF Inhibitors Market: Overview
This report on the TNF inhibitors market analyzes the current and future scenario of the global market. Rise in geriatric population, high prevalence of rheumatic diseases, and increase in patient preference for TNF inhibitors are major drivers of the global TNF inhibitors market.
The TNF inhibitors market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug, application, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global TNF Inhibitors Market.
Global TNF Inhibitors Market: Key Segments
The overall TNF Inhibitors Market can be segmented based on drug, application, distribution channel, and geography. Furthermore, in terms of drug, the market can be divided into adalimumab, certolizumab, etanercept, golimumab, and infliximab. The adalimumab segment is likely to account for a leading share of the global TNF inhibitors market during the forecast period, owing to wide usage of adalimumab in moderate to severe disease conditions. Based on application the market can be classified into rheumatoid arthritis, psoriasis, inflammatory bowel disease, ankylosing spondylitis, and others. Based on distribution channel, the market can be segregated into hospital pharmacy, retail pharmacy, and online pharmacy. The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Global TNF Inhibitors Market: Regional Outlook
In terms of geography, the global TNF Inhibitors Market has been categorized into five major regions and the key countries in the respective region are: North America (U.S., Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, United Arab Emirates, Saudi Arabia, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2018 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players in the global TNF inhibitors market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players operating in the global TNF inhibitors market include AbbVie, Inc., Janssen Biotech, Inc., UCB, Amgen, Inc., Pfizer, Inc., Samsung Bioepis, Biogen, Merck & Co., and Takeda Pharmaceutical Company.
The global TNF inhibitors market is segmented as given below:
- Global TNF Inhibitors Market, by Drug, 2016–2026
- Global TNF Inhibitors Market, by Application, 2016–2026
- Rheumatoid Arthritis
- Inflammatory Bowel Disease
- Ankylosing Spondylitis
- Global TNF Inhibitors Market, by Distribution Channel, 2016–2026
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global TNF Inhibitors Market, by Geography, 2016–2026
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
- North America